Revelation Biosciences (REVB) Other Non-Current Liabilities (2020 - 2025)
Revelation Biosciences (REVB) posted quarterly Other Non-Current Liabilities of $175.0 for Q3 2025, down 96.36% year-over-year from $4803.0 in Q3 2024, and down 77.74% quarter-over-quarter from $786.0 in Q2 2025.
Revelation Biosciences (REVB) Other Non-Current Liabilities (2020 - 2025) Analysis & Trends
Revelation Biosciences (REVB) has reported Other Non-Current Liabilities for 5 consecutive years, with $175.0 the latest figure, recorded in Q3 2025.
- In Q3 2025, Other Non-Current Liabilities fell 96.36% year-over-year to $175.0; the TTM figure through Sep 2025 stood at $175.0 (down 96.36% YoY), while the FY2024 annual figure was $2246.0, down 98.41% from the prior year.
- Other Non-Current Liabilities slipped to $175.0 in Q3 2025 per REVB's latest filing, from $786.0 in the prior quarter.
- Across five years, Other Non-Current Liabilities topped out at $3.5 million in Q1 2023 and bottomed at $175.0 in Q3 2025.
- Historically, Other Non-Current Liabilities has averaged $434042.6 across 4 years, with a median of $13052.0 in 2024.
- Annual changes were most pronounced in 2021 — Other Non-Current Liabilities slumped 70.3% — and 2024, when it sank 99.57%.
- Revelation Biosciences' Other Non-Current Liabilities stood at $1.0 million in 2021, then plunged by 86.01% to $141276.0 in 2023, then slumped by 98.41% to $2246.0 in 2024, then slumped by 92.21% to $175.0 in 2025.
- Business Quant data shows REVB's Other Non-Current Liabilities at $175.0 in Q3 2025, $786.0 in Q2 2025, and $829.0 in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.83 Bn | 130.98 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.79 Bn | 77.79 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.95 Bn | 59.77 Bn | 1.37 Bn |
| 4 | Moderna | 58.59 Bn | 53.46 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.93 Bn | 36.83 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.52 Bn | 28.21 Bn | 992.69 Mn |
| 7 | BioNTech SE | 27.98 Bn | 9.58 Bn | 668.28 Mn |
| 8 | Insmed | 27.42 Bn | 26.26 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.33 Bn | 26.49 Bn | - |
| 10 | Revelation Biosciences | 4.17 Mn | -7.33 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 175.00 |
| Jun 30, 2025 | 786.00 |
| Mar 31, 2025 | 829.00 |
| Dec 31, 2024 | 2,246.00 |
| Sep 30, 2024 | 4,803.00 |
| Jun 30, 2024 | 10,844.00 |
| Mar 31, 2024 | 15,260.00 |
| Dec 31, 2023 | 141,276.00 |
| Sep 30, 2023 | 209,478.00 |
| Jun 30, 2023 | 302,039.00 |
| Mar 31, 2023 | 3.51 Mn |
| Dec 31, 2021 | 1.01 Mn |
| Dec 31, 2020 | 3.40 Mn |